KATHLEEN D. LAPORTE - Corporate Board Profile

Precipio, Inc.

Filing Date	Source Excerpt
2021-04-29	Kathleen D. LaPorte Ms. LaPorte, age 59, was appointed as a director of the Company in 2018. Ms. LaPorte is an executive and venture capital investor with 30 years’ experience building innovative life sciences companies. Ms. LaPorte served as general partner with Sprout Group from 1993 to2005. Ms. LaPorte was one of the founders of New Leaf Venture Partners in 2005 and stayed with New Leaf Venture Partners until 2011. She was a co-founder of Health Tech Capital, a group of healthcare technology focused private and corporate investors. Ms. LaPorte served as chief business officer and later as CEO of Nodality, an immuno-oncology diagnostics company during the years 2014 to 2016. In addition to the above, Ms. LaPorte served as a member of the audit committee of Affymax Inc during years 2002 to2013. She currently serves as Audit Committee Chair of Bolt Biotherapeutics, and on several private company boards. Ms. LaPorte has a B.S. in biology from Yale University and an MBA from Stanford University Graduate School of Business. Ms. LaPorte’s experience complements the diverse expertise of our board with relevant skills and network from her years of involvement within the diagnostic sphere
2022-04-28	Kathleen D. LaPorte Ms. LaPorte, age 60, was appointed as a director of the Company in 2018. Ms. LaPorte is an executive and venture capital investor with 30 years’ experience building innovative life sciences companies. Ms. LaPorte served as general partner with Sprout Group from 1993 to 2005. Ms. LaPorte was one of the founders of New Leaf Venture Partners in 2005 and served as managing director until 2011. She was a co-founder of Health Tech Capital, a group of healthcare technology focused private and corporate investors. Ms. LaPorte served as chief business officer and later as chief executive officer of Nodality, an immuno-oncology diagnostics company from 2014 to 2016. In addition to the above, Ms. LaPorte served as a member of the audit committee of Affymax Inc from 2002 to 2013. She currently serves as a board member of Phoenix Biotech Acquisition Corp and 89BIO and on the Audit Committee Chair of Bolt Biotherapeutics, Inc., as well as on on several private company boards. Ms. LaPorte has a B.S. in biology from Yale University and an M.B.A. from Stanford University Graduate School of Business. Ms. LaPorte’s experience complements the diverse expertise of our board with relevant skills and network from her years of involvement within the diagnostic sphere
2023-04-25	Kathleen D. LaPorte Ms. LaPorte, age 61, was appointed as a director of the Company in 2018. ... The current members of the Audit Committee are directors Ms. LaPorte, the Chairperson of the Audit Committee, Dr. Fisher and Mr. Sandberg. ... Director Summary Compensation Table The following table provides information regarding our compensation for non-employee directors during the fiscal year ended December 31, 2022. ... Kathleen D. LaPorte Fees Earned or Paid in Cash ($) 50,000 Option Awards ($) 59,200 Total ($) 109,200.
2024-04-29	Kathleen D. LaPorte Ms. LaPorte, age 62, was appointed as a director of the Company in 2018. ... The current members of the Audit Committee are directors Ms. LaPorte, the chairperson of the Audit Committee, Mr. Sandberg and Mr. Cohen, all of whom have been determined by the Board to be independent under the Nasdaq listing standards and rules adopted by the SEC applicable to audit committee members. ... Director Summary Compensation Table The following table provides information regarding our compensation for non-employee directors during the fiscal year ended December 31, 2023. ... Kathleen D. LaPorte 50,000 Fees Earned or Paid in Cash, 17,805 Option Awards, 5,000 All Other Compensation, 72,805 Total.